Análisis de la acción Acadia Pharmaceuticals Inc. (ACAD)ACADAcadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $19.12 and an RSI of 34.575, ACADIA Pharmaceuticals is not a strong buy at this moment. The stock has seen a significant decline of 29.94% over the past 20 days, indicating bearish momentum. While the gross margin remains high at 90.81%, the recent clinical trial setbacks and lowered analyst price targets suggest caution. The main risk is the potential for further declines if the company fails to regain investor confidence, especially as the stock is already down 27.27% year-to-date.

10 analysts cover ACAD: 8 rate it Buy, 2 Hold and 0 Sell. The average price target is 31.17.